Screener
Regeneron Pharmaceuticals REGN Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,159.3 | $939.0 |
| Accrued expenses and other current liabilities | 2,966.5 | 2,876.4 |
| Finance lease liabilities | 720.0 | — |
| Deferred revenue | 684.8 | 553.0 |
| Total current liabilities | 5,530.6 | 4,368.4 |
| Long-term debt | 1,986.6 | 1,985.9 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's accrued expenses?
- Regeneron Pharmaceuticals (REGN) reported accrued expenses of $2.97B in Q2 2026.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Regeneron Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude